Uncategorized
FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubts
The FDA has once again rejected Replimune’s oncolytic virus therapy to treat advanced melanoma.
The Massachusetts-based drugmaker had been pushing for a reconsideration by the agency since the therapy was first rejected last July. At …